GlassScriptPhysician profile
Karim Rafael Harfouche
NPI 1003046897
$997.22
in general payments reported to CMS, 2019-2025
15 companies · $13.55 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $36.53 · 2021: $72.52 · 2022: $145 · 2023: $467 · 2024: $29.07 · 2025: $13.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $361.58 | 2021-2024 | Trelegy Ellipta |
| Vifor Pharma, INC. | $85.95 | 2022-2023 | Veltassa |
| Novo Nordisk INC | $76.55 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $71.78 | 2019-2023 | Farxiga |
| Pfizer INC. | $62.15 | 2019-2022 | |
| Exact Sciences Corporation | $52.19 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $46.59 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $46.59 | 2019-2022 | |
| Aprecia Pharmaceuticals, LLC | $45.80 | 2023 | Spritam |
| Abbott Laboratories | $42.73 | 2019-2023 | Freestyle Libre |
| Mannkind Corporation | $22.78 | 2019 | |
| Genentech USA, INC. | $22.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.59 | 2019 | |
| Phadia US INC. | $17.38 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Harfouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.